Drugs / Brivoligide
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03797612 | Jan 2021 → Jan 2022 | neuropathy, painful | Adynxx, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04104919 | Jan 2021 → Jan 2022 | — | Adynxx, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT02807428 | Feb → Oct 2017 | — | Adynxx, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02081703 | May 2014 → Jun 2015 | — | Adynxx, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01731730 | Jan → Oct 2013 | — | Adynxx, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Brivoligide | “6 mL solution for intrathecal injection with 660 mg of AYX1 (Brivoligide)” NCT02807428 ↗ |
| Known as | AYX1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02081703 ↗ |
| Known as | Brivoligida | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297228 ↗ |
| Action | Inhibit | “Early growth response protein 1 inhibitor” CHEMBL4297228 ↗ |
| Route | Intrathecal | “3mL solution for intrathecal injection with 110 mg of AYX1” NCT01731730 ↗ |
| Target | EGR1 | “Early growth response protein 1 inhibitor” CHEMBL4297228 ↗ |